Professor Hsueh-Chia Chang is the Bayer Professor of Chemical and Biomolecular Engineering at the University of Notre Dame. He has been at Notre Dame since 1987 and has served as the department chair and the director of the Center for Microfluidics and Nanofluidics. His research is in the area of micro/nanofluidics and diagnostics, particularly integrated devices for the isolation and characterization of exosomes and other nanocarriers. His research has resulted in 19 patented technologies, eight of them have been licensed by four startups: Cubed Laboratories, AgenDx, ImpeDx and Aopia Biosciences. Products developed from these IPs include CRDTM Botrytis Detection kit by CubedLabs and NanoExTM exosome purification technology by Aopia Bio. Professor Chang served as the Chief Scientific Advisor of FCubed LLC (predecessor of CubedLabs) for 4 years. He co-founded Aopia Bio in 2019 and currently serves as its interim CTO and Board member. Professor Chang has published more than 300 papers and has a Google h-index of 79. He is the co-author of a seminal book in microfluidics: "Electrokinetically Driven Microfluidics and Nanofluidics" by Cambridge University Press in 2009. Professor Chang founded a new journal, Biomicrofluidics of the American Institute of Physics, in 2006 and served for 12 years as its Chief Editor. More than 35 PhD and post-doc students from his laboratory have embarked on academic careers as tenure-track professors in all engineering and science disciplines over 5 continents (15 in the US), including Duke, Imperial, Johns Hopkins etc. They include a chancellor, a Provost, three Department Chairs, four endowed chairs and five NSF Career Awardees. Industrial alumni from his group hold manager/director positions at Merck, Gilead, Alcon, Genentech and other major biotech and world-leading microfluidic companies. Professor Chang is a fellow of APS, NAI and AIMBE. His microfluidics work has been recognized by the Frenkiel Award from APS, the Lifetime Achievement Award from AES and the 1st Source Bank Commercialization Award. He has also won the Notre Dame Provost Research Achievement Award and was recognized at half time during the 2024 game against Stanford.

I hold a BSc (Hons) from National University of Singapore, a PhD from SUNY at Buffalo and received postdoctoral training at Columbia University. For nearly three decades, I have led independent research groups across multiple institutions in Singapore, with a consistent focus on disease mechanisms and therapeutic development. My current research centers on extracellular vesicles (EVs), particularly MSC-derived EVs, exploring their production, characterization, and clinical applications. I was named a Clarivate Highly Cited Researcher (2021–2024) and received the 2023 ISEV Special Achievement Award for Stem Cell EV Research. As an inventor, I hold over 100 granted patents across 12 families and have founded three biotech start-ups, one of which completed a Phase 1 clinical trial using topical MSC-exosomes for psoriasis in 2022.

Sven Kreutel studied biology at the University of Hohenheim in Stuttgart, Germany. After his graduation in biology, he received his PhD in microbiology and protein biochemistry at the University of Hohenheim under Prof. Dr. Andreas Kuhn and Dr. Dorothee Kiefer working on the light sensing and signal transduction in photosynthetic bacteria. Since then he worked in different sales and sales manager positions within the life science industry from clinical research over biology to nanoparticle sciences. In 2021 he was appointed as CEO of the American subsidiary of Particle Metrix.